Mark Cuban warns that artificial intelligence may accelerate the arms race between insurers and providers, driving up costs and making U.S. healthcare even harder for patients and employers to navigate
When Marc Andreessen recently claimed on X that artificial intelligence is already outperforming nearly all human doctors, he reignited debate about the future of AI in medicine. The post, which referenced OpenAI CEO Sam Altman's comments on the accuracy of GPT-5.6 compared to physicians, quickly drew a pointed response from Mark Cuban. But Cuban's concern wasn't about whether AI can diagnose illness-it was about how entrenched interests in the U.S. healthcare system might use AI to reinforce the very problems patients and employers already face.
AI Meets Healthcare Bureaucracy
Cuban argued that a significant portion of doctors' time-at least a quarter-is consumed by navigating administrative hurdles imposed by large healthcare conglomerates. These organizations, which include insurers and pharmacy benefit managers (PBMs), have built complex systems that often make care more expensive and difficult for both providers and patients. Cuban warned that as AI tools become more sophisticated, these same conglomerates are likely to deploy their own AI agents to further delay, deny, or complicate care, all in the name of controlling costs and maximizing profits.
This dynamic, Cuban suggested, could turn into a technological arms race: for every AI tool designed to help doctors and patients, there will be another built to protect the interests of insurers and middlemen. The result may not be better care, but simply a faster, more opaque version of the same adversarial process that already frustrates patients and employers.
Insurers and Middlemen: The Real Winners?
According to reporting by TheStreet, Cuban believes that the core issue isn't whether AI can read an MRI or spot a rare condition. The real problem is what happens after AI delivers its answer. Insurers and PBMs profit from the current complexity, charging fees to navigate a system that few outsiders truly understand. If AI were to make healthcare more transparent and affordable, it would threaten their business models-so they have every incentive to use AI to maintain their advantage.
Cuban has called for a fundamental shift: eliminating unnecessary middlemen and building AI agents that contract directly with providers. He argues that as long as employers and employees remain in the dark about the true cost of care, the system will continue to favor those who profit from confusion and opacity. In his view, no company in the U.S. can currently say with certainty what it actually pays for employee healthcare, because the real numbers are hidden by carriers, PBMs, and other intermediaries.
Cost Pressures and Patient Impact
Cuban's frustration is rooted in the financial realities facing American households. According to a 2025 West Health-Gallup survey, about one in three U.S. adults-roughly 82 million people-made at least one daily financial trade-off last year to afford healthcare. These trade-offs included rationing prescriptions, taking on debt, or delaying care. Meanwhile, Mercer projects that average health benefit costs per employee will exceed $18,500 in 2026, marking the steepest annual increase in 15 years.
Hospitals are also feeling the squeeze, hiring revenue cycle management firms that can charge up to 10% of revenue just to contest insurance denials. Insurers, for their part, are already using AI to scrutinize contracts and identify ways to limit payouts. Cuban contends that these trends show AI is not a new player in the fight-it's already being used to reinforce existing power structures, not to help patients.
Reform Efforts and Persistent Risks
Since 2022, Cuban has tried to disrupt the status quo by co-founding Cost Plus Drug Company, which sells generic medications at a transparent markup without PBMs or hidden pricing. He has also supported the Break Up Big Medicine Act, introduced in February 2026, which would require large insurers to separate their PBM, provider, and drug distribution businesses. Cuban argues that vertical integration allows these companies to obscure costs and control outcomes, making real reform impossible without structural change.
He is also backing startups like Claimable, which use AI to help patients fight insurance denials. Yet Cuban remains skeptical that better technology alone will lower costs or improve care. For every tool that helps patients, he sees insurers developing their own AI to push back even harder. The underlying incentives, he argues, remain unchanged-and until they shift, AI may simply accelerate the cycle of denials and appeals rather than breaking it.
What It Means for Employers and Patients
For employers, Cuban's warning is clear: AI is unlikely to make healthcare costs more transparent or manageable as long as the system is designed to keep them in the dark. The organizations that understand the true economics of care are using AI to maintain their advantage, not to level the playing field. For patients, new AI-powered tools may help contest denied claims, but they are entering an arms race where insurers are just as quick to deploy their own technology to resist payouts. Cuban's message is that real progress will require eliminating or reforming the middlemen who profit from complexity-not just adding smarter algorithms to the mix.
According to the Kaiser Family Foundation's 2025 Employer Health Benefits Survey, the average annual premium for employer-sponsored family health coverage reached $24,500, with workers contributing $7,800 on average. These rising costs, combined with persistent lack of transparency, continue to put pressure on both employers and employees, reinforcing Cuban's concerns about the direction of U.S. healthcare spending.
Pharmacy benefit managers (PBMs) play a central but often misunderstood role in the U.S. healthcare system. PBMs negotiate drug prices with manufacturers, create formularies (lists of covered medications), and process prescription claims for insurers and employers. While they claim to lower costs through bulk purchasing and negotiation, critics argue that PBMs often obscure true drug prices, collect rebates that may not be passed on to consumers, and contribute to the overall complexity and opacity of healthcare billing. Recent legislative proposals, such as the Break Up Big Medicine Act, aim to increase transparency and reduce conflicts of interest by requiring insurers to separate their PBM operations from other business lines. For consumers and employers, understanding how PBMs operate is key to grasping why healthcare costs remain high and why reforms targeting these intermediaries are at the center of current policy debates.
